Synthetic-Lethality Screening with PARP1 inhibition
PARP1 plays a central role in DNA repair and is a well-established target across multiple cancer types. Understanding the vulnerabilities associated with PARP1 biology, together with advances in targeted protein degradation and molecular-glue discovery, may help uncover new therapeutic opportunities.
At AACR 2026, WuXi Biology scientists highlighted complementary approaches spanning whole-genome synthetic-lethality screening, molecular-glue-focused high-throughput screening, and proximity-labeling technologies.
The work presented in this poster applies in vitro and in vivo screening in liver cancer models to identify potential genes that are co-lethal with PARP1 loss or inhibition. It also explores the discovery of CRBN-dependent and CRBN-independent degrader hits, together with a proximity-labeling and proteomics strategy to support candidate E3-ligase identification and prioritization.
Poster_Synthetic-Lethality-Screening-with-PARP-inhibition-and-Non-CRBN-Degrader-ID
Related Content
Many oncology drug candidates with promising preclinical activity ultimately fail because safety liabilities emerge too late in development. An integrated...
VIEW RESOURCEBispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...
VIEW RESOURCE